Glenmark Pharma introduces Vancomycin Injection in U.S. market

The product is bioequivalent and therapeutically equivalent to the reference listed drug by Fresenius Kabi USA, LLC.

Cipla achieves highest-ever annual revenue of Rs. 28,163 crore in FY26

The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market

Bayer posts strong Q1 2026 results as Crop Science surge lifts earnings & outlook

Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros

Revvity wins FDA clearance for total testosterone test

Suven Life Sciences reaches 76% milestone in Phase 3 masupirdine trial for Alzheimer’s agitation

The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies

Syngene appoints Maninder Kapoor Puri as CHRO and Abhijit Zutshi as CCO

Both join the leading CRDMO’s executive committee to drive global people strategy and commercial expansion

Granules India Q4FY26 revenue jumps 23% to Rs 14,706 million; FY26 revenue at Rs 53,656 million

The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform

Cipla wins USFDA nod for first generic of Ventolin HFA strengthening respiratory push

The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA

Cipla’s generic Ventolin HFA secures USFDA approval

Approval for Albuterol Sulfate inhalation aerosol enables Cipla Limited to enter the $1.5 billion U.S. albuterol market

Vision Engineering appoints Harry Curtis as Technical Director, joins Board

In his new role, Curtis will lead the formulation and execution of the company’s global technical strategy